New Treatment for Liver Cancer Gets FDA Approval
The FDA expanded the use of regorafenib to treat certain patients with the most common form of liver cancer diagnosed in the U.S. – hepatocellular carcinoma.
Progress Against Cancer
The FDA expanded the use of regorafenib to treat certain patients with the most common form of liver cancer diagnosed in the U.S. – hepatocellular carcinoma.
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
The FDA issued the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma.
The FDA expanded the use of the immunotherapeutic pembrolizumab to include the treatment of certain patients with Hodgkin lymphoma.
A molecularly targeted therapeutic was approved for use in combination with any aromatase inhibitor for the treatment of postmenopausal women with a certain form of breast cancer.
Study reports that cancer type and mortality differs among ethnic groups, suggesting a need for targeted public health efforts. A new study suggests that the growing Hispanic population in the United States may experience...
A study suggests that diet during adolescence and early adulthood may be associated with premenopausal breast cancer risk.
Study: Women who have a false-positive screening mammogram are more likely to delay their next breast cancer screening.
The FDA expanded the use of a targeted therapy for a form of non-Hodgkin lymphoma called marginal zone lymphoma.
An immune checkpoint inhibitor – a form of immunotherapy – has had its use expanded for use in the treatment of bladder cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More